Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin

Interventions

DRUG: SGN-40
DRUG: rituximab
DRUG: gemcitabine

Sponsor

Seagen Inc.

Collaborators

[object Object]